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ABSTRACT 
Susceptibility of 112 strains of Staphylococcus aureus 
obtained from Dameron Hospital, Stockton, California was 
tested with 18 antimicrobials . The MIC method was used with 
the following antimicrobials : tetracycline, oxacillin, 
penicillin, ampicillin, vancomycin, cefazolin, erythromycin, 
clindamycin, gentamycin, rifampin, trimethoprim-
sulfamethoxazole, chloramphenicol, and cefotaxime . The 
standard Kirby-Bauer disc diffusion method was used to test 
neomycin, tobramycin, and amikacin . Methicillin, oxacillin, 
and nafcillin were tested with a modified Kirby-Bauer method, 
which included the addition of a 4% salt supplement to the 
media, incubation at 32C, and readings at both 24 and 48 
hours. 
Comparing results of this study with those of Hall 
(1975), suggested that resistance to the following 
antibiotics has increased: penicillin, ampicillin, 
erythromycin, neomycin, gentamycin, methicillin, oxacillin, 
nafcillin, cefazolin, and clindamycin . Resistance to 
tetracycline has decreased. No resistance to chloramphenicol 
or vancomycin was encountered in either study . 
Of the 112 strains studied, 13 . 4% were susceptible to 
all antibiotics tested. Twelve patterns of resistance were 
identified : 0 . 9% were resistant to neomycin only, 1.8% to 
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erythromycin only, 63.9% to both penicillin and ampicillin, 
and 20 . 0% were multiply- resistant . Nine patterns of 
multiple-resistance were found, involving a minimum of three 
antibiotics and a maximum of nine . 
Three MRSA strains were identified from out-patient 
isolates; no in-patient isolates were methicillin-resistant . 
The study suggests that MRSA strains are not a problem at 
Dameron Hospital, but identification of this group would be 
more accurate if incubation of the MIC panels is maintained 
for at least 24 hours at ~35C . It was found that the MIC 
method of antimicrobial susceptibility testing is more 
reliable than the Kirby-Bauer disc diffusion method for 
detection of methicillin-resistance. Problems involved in 
identification of heteroresistant staphylococci are 
discussed . 
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I . INTRODUCTION 
Staphylococci are Gram positive cocci, 0 . 5- 1 . 5~ in 
diameter occurring ln grape-like clusters or occasionally ln 
tetrads, pairs, and short chains of three to four cells . 
Staphylococci are currently included with the genera 
Micrococcus and Planococcus in the family Micrococcaceae . 
The genus Staphylococcus is presently composed of 23 species, 
12 of which occur in humans (Howard and Kloos, 1987) . 
Because Staphylococcus aureus is a pathogen, or potential 
pathogen, it is recognized as the most important species of 
the genus . Coagulase production has traditionally been 
considered a distinctive and unique characteristic of ~. 
aureus. Recent studies (Hajek, 1976; Philips Jr . and Kloos, 
1981; Biberstein et al . , 1984), however, have shown that the 
ability to clot plasma (a positive coagulase test) is also 
characterestic of ~. intermedius and ~· hyicus, subspecies 
hyicus. Since S . intermedius and~ - hyicus hyicus occur only 
in nonhuman animals (Kloos and Jorgensen, 1985), it is 
assumed that any coagulase positive staphylococci isolated 
from humans is~ - aureus . Recent studies (Howard and Kloos, 
1987) have found that about 3% of ~- aureus are coagulase 
negative and therefore biochemical characteristics should 
also be used to identify this species with accuracy . 
In the late 1950 ' s and early 1960's S . aureus emerged as 
a major cause of morbidity and mortality ln hospitals . Some 
1 
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strains of this organism began to show resistance to 
penicillin due to the production of a B-lactamase enzyme 
called penicillinase (Thornsberry, 1984) . This enzyme lyses 
the beta-lactam ring in the "nucleus" of the molecule, 
inactivating the drug . Resolution of the problem was thought 
to have been achieved with the introduction of a new group of 
penicillins known as the penicillinase-resistant penicillins 
(PRP ' s) . The first, methicillin, was introduced in 1959, 
followed by nafcillin and oxacillin, shortly after. However, 
almost concurrently, ~. aureus strains resistant to 
methicillin, nafcillin and oxacillin, were recognized in 
Britain, throughout Europe, and more recently in the United 
States (McNeil and Solomon, 1985; Jorgensen and Thornsberry, 
1987). These strains came to be referred to as methicillin-
resistant or MRSA (methicillin-resistant Staphylococcus 
aureus). Today it is recognized that resistance to one PRP 
implies resistance to the other two (Sherris, 1984) . The 
term MRSA for methicillin-resistance is used regardless of 
whether the susceptibility testing is performed with 
methicillin, oxacillin or nafcillin . In practice, most 
clinical laboratories determine methicillin-resistance using 
oxacillin because of its greater in vitro stability . 
MRSA strains ·were first isolated from patients in large 
tertiary care hospitals, and later in convalescent homes and 
rehabilitation facilities (Jorgensen et al . , 1984; 
Thornsberry, 1984). More recently they have appeared ~n 
primary care facilities, with estimates of 4 . 6- 6 . 0% 
incidence (McGowen, 1988) . Many MRSA strains are also 
resistant to several commonly used antibiotics, besides 
methicillin (Welch and Southern, 1984; Putland and Guinness, 
1985). 
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The first study of ~ . aureus from the Stockton community 
was conducted by Hall (1975) . In his survey of 136 strains 
from patients at Dameron Hospital, Hall investigated the 
relationship between antibiotic pattern (antibiogram), 
enzymatic activity, and phage type. To test susceptibility, 
Hall used the Kirby-Bauer disc diffusion method and 20 
antibiotics including methicillin, oxacillin, and nafcillin . 
One of Hall's most significant findings, relative to the 
present study, was that all strains were 100% susceptible to 
the PRP's . 
Hall ' s results, and others obtained prior to 1980, are 
difficult to evaluate because of the problems involved in 
testing susceptibility of this organism (Thornsberry, 1984 ; 
Robinson et al., 1986). At a meeting of the California 
Association for Medical Laboratory Technology (April 30, 
1986, St . Joseph's Hospital in Stockton, California), Leon 
Sabath, a visiting lecturer, pointed out that these 
difficulties reside in the fact that a single MRSA colony may 
contain both susceptible and resistant subpopulations. Such 
populations frequently described as "heteroresistant" (Kayser 
and Muller, 1983; McDougal and Thornsberry, 1984). Sabath 
indicated that erroneous results are often obtained because 
test conditions favor the faster growing susceptible 
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population . He presented a number of observations which can 
be used to aid in the detection of heteroresistance, 
including faint growth occurring within the zone of 
inhibition for any of the PRP's, colonies of the same strain 
exhibiting varying growth rates, and heterogeneity of 
resistance within the same strain . In a video entitled "In 
Vitro Detection of Methicillin Resistant Staphylococcus", 
prepared by Eli Lilly Co . (Indianapolis, Indiana), 
Thornsberry of the Centers for Disease Control in Atlanta, 
Georgia and Jorgensen of the University of Texas Health 
Science Center, San Antonio, Texas, suggest the use of three 
additional observations to aid in the detection of MRSA: (1) 
an intermediate susceptibility result to one or more PRP; (2) 
concurrent resistance (referred to as multiple resistance) to 
one or more of several other antibiotics including 
erythromycin, chloramphenicol, tetracycline, clindamycin and 
the aminoglycosides; (3) a cephalothin MIC between 1 & 16 
mcg/ml. 
At the aforementioned meeting of the California 
Association for Medical Laboratory Technology, it was noted 
that although all oells of a heteroresistant strain are 
genotypically resistant to the PRP's, only a minority exhibit 
phenotypic resistance. Factors promoting expression of 
phenotypic resistance are : (1) incubation at temperatures 
lower than 37C (30-35C), (2) incubation for at least 24 
hours, but not longer than 48 hours, (3) increasing the 
content of salt in the medium to between 2-4%, (4) 
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suspending, rather than grow~ng the inoculum to the standard 
turbidity of 108 CFU (Colony Forming Units)/ml, and (5) using 
media incorporating 0-lactam compounds (Jorgensen and 
Thornsberry, 1987) . In Hall's (1975) study, these techniques 
were not utilized . 
The strains used by Hall (1975) were not available for 
retesting. Whether he would have had any MRSA if he had used 
the special procedures for detecting these strains cannot be 
determined. According to Nahhas (personal communication), 
the extent of resistance of ~. aureus strains is not known in 
the Stockton community because none of the three major 
hospitals use all the special procedures needed to detect 
them . The importance of ~. aureus as a cause of local 
infections (skin, eyes, nose, throat, urethra, vagina, and 
gasterointestinal tract) is well recognized . More serious 
invasive staphylococcal infections rarely occur in healthy 
individuals but can occur in individuals whose immune systems 
are compromised (immune deficiency, leukocyte defects, etc . ) . 
Predisposing factors including traumatic wounds, burns, 
surgical incisions, pacemakers, intravenous catheters, 
diabetes mellitus, alcoholism, coronary heart disease, and 
various malignancies, can lead to more serious invasive 
staphylococcal conditions . With the emergence of methicillin-
resistance and implied resistance of the cephalosporin 
antibiotics (Thornsberry and Jorgensen, 1985), as well as 
increasing multiple resistance, knowledge of the antibiotic 
pattern of local strains of~ . aureus becomes important . 
It is the purpose of this investigation to : 
1 . Report on antibiotic susceptibility of ~ . aureus 
isolates obtained from Dameron Hospital. 
2 . Determine if methicillin-resistance exists 
among these isolates using the recommended 
procedures . 
3 . Determine the extent of multiple resistance, ~ . e . 
resistance to antimicrobials in addition to the 
penicillins . 
4 . Compare results obtained in this study with those 
of Hall (1975). 
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II . MATERIALS AND METHODS 
One hundred and twelve strains of Staphylococcus aureus 
were isolated at the clinical laboratory of Dameron Hospital, 
Stockton, California , between September 25 , 1987 and December 
31, 1987. These strains were identified as~. aureus at the 
hospital microbiology department using Microscan Gram 
Positive Combo panels or trays (Microscan, Baxter Scientific 
Products, Sacramento, California) . 
Biochemical and Enzymatic Testing 
The battery of tests in the panel consists of 27 
biochemical and enzymatic tests, 18 of which are used for the 
identification of staphylococci (Appendix I) . The procedures 
used in these tests are detailed below, and the principles 
involved are given in Appendix II. 
Instructions for inoculation of the tray are as follows : 
From each primary isolation plate, three to five colonies are 
selected to inoculate a 5-ml brucella broth tube. The tube 
is then incubated for four to six hours at 35C which allows 
the bacteria to grow to the stationary phase of about 109 
CFU/ml . One-half ml of the suspension is then pipeted into a 
tube containing 25 ml sterile distilled water . This 1 : 50 
dilution produces a concentration of approximately 2 x 106 
CFU/ml . The Gram Positive Combo is inoculated by placing a 
transfer lid of metal prongs into a trough containing the 
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preparation and situating the lid of prongs over the test 
panel so that the prongs (each holding 5 mel of inoculum) dip 
into the wells containing media and/or antibiotics . The 
small amount of inoculum contained on each prong is pulled 
into the media by capillary action. Following inoculation, 
the tray is incubated for 18-20 hours and read on a scanner 
(Touohscan) connected to a computer. Positive reactions are 
recorded by the microbiologists and transferred to the 
computer memory whose data base identifies the species and 
translates the information into a biotype or I.D . number 
(Appendix III). 
The panels used in this project were transferred to the 
microbiology laboratory at the University of the Pacific and 
reincubated for an additional 24 hours at 32 ± 1C to allow 
time for slower biochemical reactions to develop . The longer 
incubation period at a lower temperature was also intended to 
promote the growth of any existing methicillin-resistant 
subpopulations . After a total of 42-44 hours, the final 
results were recorded. 
In addition to the tests from the Gram Positive Combo 
tray, a number of supplemental enzymatic tests were performed 
at the university, including coagulase, DNAse, and hemolysis. 
The purpose of these additional tests was to confirm the 
identity of the isolates and compare results with those of 
Hall (1975). Each strain was reisolated on mannitol salt 
agar (Difco - Detroit, Michigan) by dipping a sterile cotton 
swab into the growth well of the test panel and using it to 
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apply a drop of bacterial growth to the agar plate . A 
sterile loop was used to streak . the plate after which it was 
incubated for 24 hours at 37C in an inverted position . Three 
to five well- isolated 24 - hour colonies were selected to 
prepare a suspension in sterile distilled water with a 
turbidity (approximately lOB CFU) equal to the 0.5 MacFarland 
barium sulfate standard purchased from the Remel Co (Lenexa, 
Kansas) . This suspension was used to perform all additional 
antimicrobial and biochemical testing . Furthermore, a tryptic 
soy agar slant was inoculated from each suspension and saved 
as a stock culture. The enzymatic tests are described below . 
Coagulase 
To test for coagulase production, two drops of the 
bacterial suspension were transferred to a tube 
containing 0.5 ml of reconstituted rabbit plasma 
(Difco) . The mixture was incubated for 24 hours at 
37C and examined for clot formation, a positive test . 
Deoxyribonuclease (DNAse) 
This procedure utilizes Difco DNAse test medium 
containing methyl green. Methyl green combines with 
DNA in the medium only if the DNA is in its most 
polymerized state (Smith et al., 1969). If the test 
organism produces DNAse, the DNA becomes 
depolymerized, freeing the methyl green . The result 
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is the formation of a clear zone around the colony. 
Hemolysis 
Hemolysis was observed on blood agar plates (5% sheep 
blood in tryptic soy agar) . A clear zone around the 
colonies resulting from complete lysis of the red 
blood cells indicates a positive result . 
Antimicrobial Susceptibility Testing 
Most susceptibility testing was accomplished with the 
Microscan Gram Positive Combo panel . The tray was inoculated 
at the microbiology lab of Dameron Hospital as described 
earlier. The test panel, which utilizes the MIC (minimum 
inhibitory concentration) method of susceptibility, contains 
13 antimicrobials in several dilutions (Appendix III). The 
MIC for a particular antimicrobial is the lowest 
concentration of that antibimicrobial which inhibits growth . 
After the test panels were incubated for 18-20 hours at 
Dameron Hospital, the results were recorded on the Touchscan 
computer along with those of the biochemical tests . 
Identification and biotype generation is done by the computer 
at this time. Following transport to U.O . P. the trays were 
reincubated, as indicated earlier, to allow time for the 
slower growing methicillin-resistant strains to express this 
characteristic and for slower chemical reactions to develop . 
The results were interpreted using a chart published by 
Baxter Scientific Products (Appendix III). 
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Six antibiotics (Appendix IV - methicillin, oxacillin, 
nafcillin, neomycin, tobramycin, and amikacin) were tested 
with the Kirby-Bauer disc diffusion method. The tests were 
conducted on Difco Mueller-Hinton medium . The medium is 
standardized so that the only variable in testing is the 
susceptibility of the test organism to a specific 
concentration of antibiotic . The agar plates were prepared 
by rehydrating the media according to the manufacturer's 
instructions on the bottle and then pouring the molten agar 
into screw-capped tubes, each holding 20 mls. After 
sterilizing the media at 121C and 15 p . s.i . for 15 minutes, 
the liquified agar was aseptically poured into sterile 
plastic 100 mm petri dishes. The three penicillinase-
resistant penicillins (methicillin, oxacillin, and nafcillin) 
were tested on Mueller-Hinton agar containing 4% sodium 
chloride which was added to the powdered medium before 
rehydration. The purpose of using all three PRP's was to 
determine if susceptibility or resistance is the same for 
all, under the same standardized conditions. Oxacillin is 
also on the Gram Positive Combo trays and therefore a 
comparison between the MIC and disc diffusion methods can be 
made for that antibiotic . 
Each freshly prepared agar plate was streaked with the 
bacterial suspension using a sterile cotton swab . The plates 
were evenly streaked in three directions to insure a uniform 
distribution of bacteria. After allowing the plates to dry 
for 5 - 15 minutes, paper discs impregnated with antibiotics 
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were dispensed onto the surface of the plates . Discs 
containing methicillin, oxacillin, and nafcillin were placed 
on the agar containing 4% salt . Discs of amikacin, 
tobramycin, and neomycin were tested on agar without the salt 
supplement . These last three were tested because Jorgensen 
and Thornsberry (1987) suggest that results of aminoglycoside 
susceptibility tests can be useful in determining methicillin-
resistance. The plates were inverted and incubated (at 37C 
for the aminoglycosides and 32C for the PRP ' s) for 24 hours . 
Those containing the three PRP ' s were incubated an additional 
24 hours for a total of 48 hours, according to the 
recommended procedures (Jorgensen and Thornsberry, 1987) . 
The zone of inhibition was then measured in millimeters and 
interpreted according to Appendix IV . 
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III . RESULTS 
Biochemical and Enzymatic Tests 
The 24 hour results listed ~n Table I, with the 
exception of DNAse, hemolysis, and coagulase were those 
obtained from the panels that were incubated in the 
microbiology department at Dameron Hospital. I found that 
some strains are positive for certain characteristics only 
after extended incubation . This is particularly true of PGT, 
urease, raffinose, lactose, and to a lesser extent of 
arginine, IDX, PYR, arginine, and mannitol . 
Table I also shows the results of the t hree additional 
tests performed at U . O.P . Hemolysis and coagulase were read 
at 24 hours, but most DNAse test results were inconclusive at 
24 hours and reincubated further, read, and recorded at 48 
hours incubation. Ninety-eight percent of the strains were 
hemolytic, 100% produced DNAse, and 95% were coagulase 
producers . 
Antimicrobial Susceptibility Tests 
The results of these tests were interpreted using the 
charts in Appendixes III and IV. Those strains showing 
intermediate results for certain antibiotics were 
interpreted, and categorized respectively, as either 
susceptible or resistant depending on how close the results 
were to each of those categories . This is a common practice 
in clinical laboratories in order to place an isolate in the 
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susceptible or resistant category only . 
Tables II and IV show raw figures of MIC ' s of 13 
antimicrobials for each in-patient and out-patient isolate 
derived from computer printouts at the hospital . Tables III 
and V show the data for the same strains by the Kirby- Bauer 
disc diffusion method as it relates to six antimicrobials, 
five of which are not present in the MIC wells of the Gram 
Positive Combo panel . Table VI is a summary presenting the 
MIC and disc diffusion results as percent resistance . Table 
VII shows the various patterns of resistance . 
Of the 112 isolates tested (Table VII), 13.4% (8.5% in-
patient and 15.4% out-patient) were susceptible to all 
antimicrobials . There was no resistance (Table VI) by any of 
the strains to vancomycin (VA), trimethoprin-sulfazoxazole 
(TXS), chloramphenicol (C), and cefotaxime (Cft). The 
greatest resistance was to penicillin and ampicillin, each 
showing 84 . 8% resistance (89 . 4% in-patient and 81 . 5% out-
patient) . Resistance to erythromycin was seen in 14 . 3% of 
the strains (21 . 3% in-patient and 9 . 2% out-patient). Three 
isolates (strains #10284, 11126, and 11299) or 4.6% of out-
patient strains were resistant to oxacillin (#11126 showed 
resistance only after extended incubation), yet no MRSA were 
found among in-patient isolates . These same isolates were 
also completely resistant to oxacillin, methicillin, and 
nafcillin by the Kirby-Bauer disc diffusion method (Table V), 
although the results here are not so straight forward . Two 
columns are presented for each of the PRP ' s because the zone 
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of inhibition for these antibiotics was read at both 24 and 
48 hours . For oxacillin and nafcillin, the additional 
incubation period resulted in a higher percentage of strains 
expressing resistance . Only the methicillin results for the 
disc diffusion method coincide with the oxacillin results for 
the MIC method (0% resistance in in-patient strains, 4.6% 
resistant in out-patient strains) . 
Although Table IV shows MIC's to cefazolin of 8, 1, 
and 1 respectively for the three MRSA strains 10284, 11126, 
and 11299, it is standard to report methicillin-resistant 
strains as resistant to the cephalosporins regardless of ~n 
vitro results (NCCLS, M2-A3, 1984). This adjustment was 
automatically made by the computer and, therefore, was made 
in compiling Tables VI and VII . 
Various patterns of resistance were seen in 86 . 6% of the 
isolates (Table VII) . Resistance to a single antibiotic was 
seen in three strains : Two strains (1.8%) were resistant to 
erythromycin and one strain (0 . 9%) was resistant to neomycin . 
Almost 64% were resistant to penicillin and ampicillin only. 
Multiple resistance is represented by n i ne patterns . The 
pattern of multiple resistance encountered most often was 
found in 7 . 4% (17 . 0% in-patient and 1 . 5% out-patient) of the 
isolates . This involved resistance to penicillin, 
ampicillin, and erythromycin . 
The three MRSA isolates showed the greatest multiple 
resistance (penicillin, ampicillin, oxacillin, cefazolin, 
erythromycin, neomycin, and tobramycin) . 
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IV . DISCUSSION 
My interest in the biochemical profile of S . aureus 
isolates was only secondary. Since the reading of the tests 
at the hospital is done after 18-20 hours incubation, I 
reincubated the panels to determine if any changes occurred . 
The results suggest that a minimum of 24-hours incubation, 
and possibly longer, is necessary for PGT, urease, raffinose, 
lactose, and to a lesser extent arginine, IDX, PYR and 
mannitol to show a positive reaction . This is important in 
terms of proper recognition by the data base in the memory of 
the Touchscan computer. Staphylococcus aureus strains with 
such negative results are often identified as ~ . aureus , but 
also flagged by the computer as "atypical". 
The three tests I used to confirm the identity of ~ 
aureus were DNAse, hemolysis and coagulase (100%, 98%, and 
95% positive, respectively). My results are in complete 
agreement with Hall (1975) with respect to the DNAse test . 
The ability to break down DNA has long been considered a 
characteristic of~. aureus (Barry, 1973) . 
Eighty-seven percent of Hall ' s strains tested positive 
for hemolysis compared with 98% in my study . I cannot 
explain this discrepancy . Both results are 1n agreement with 
the observations of Kloos and Jorgensen (1985) who report 
that "most" strains of S. aureus are strongly hemolytic . 
My results indicate that the use of the coagulase test 
as the only criterion for identification of S . aureus is 
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insufficient . In this study, SlX of 112 strains (5%) were 
coagulase negative . Kloos and Jorgensen (1987) report 3% of 
~ . aureus strains are coagulase negative . Since Hall (1975) 
depended entirely on a positive coagulase test to identify S . 
aureus, it is possible that he excluded a number of strains 
because of negative results . 
The emphasis in this study is on the antibiogram of the 
isolates . It should be pointed out at this time, that the 
expression "in-patient isolate" is not necessarily synonymous 
with "hospital acquired (nosocomial) isolate" . These strains 
may have been acquired during the stay of the patient in the 
hospital or may have been brought into the hospital with the 
patient. The records of the in-patients were not availabe to 
determine how the infection was acquired. In contrast to the 
above, the terms "out-patient isolate" and "community 
acquired isolate" are most likely exchangeable . These 
strains of S. aureus were obtained from either out-patients 
or emergency room-patients with no history of having an 
earlier admission to Dameron Hospital. The above 
clarification is important because of the trend in the 
literature to compare "hospital acquired " and "community 
acquired" strains especially as this relates to penicillin 
resistance . 
There appears to have been a general increase in 
resistance to antimicrobials by ~ . aureus in the Stockton 
community since Hall completed his study in 1975 . Resistance 
to the following antimicrobials has increased in the last 12 
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years : penicillin (79 to 84 . 8%) ; ampicillin (79 to 84 . 8%); 
erythromycin (3 . 5 to 14 . 3%); neomycin (0 to 6 . 3%); gentamycin 
(0 to 3.6%); methicillin, oxacillin, nafcillin, cephazolin (0 
to 2.7%); and clindamycin (0 to 0.9%) . Resistance to both 
chloramphenicol and vancomycin has remained at 0 . 0% . The 
only antimicrobial to which strains of ~ . aureus have become 
more susceptible is tetracycline (15 to 3.6%). This 
observation is in agreement with a trend noted by Hall 
(1975), that resistance to tetracycline has been decreasing 
over the years. Statistical significance of changes in 
resistance to the drugs mentioned are indicated in Table 
VIII . 
Hall (1975) found no significant difference in 
resistance between in-patient isolates and out-patient 
isolates. This is also the case in my study, except for 
erythromycin. Over 21% of in-patient isolates showed 
resistance to erythromycin but only 9 . 2% of out-patient 
isolates expressed resistance . A partial explanation of this 
difference may be due to the inability to determine if some 
in-patient strains are "hospital acquired" or "community 
acquired", as explained earlier. The increase in 
erythromycin resistance since 1975 (3.5 to 14 . 3%) is contrary 
to a trend of decreasing reisistance noted by Hall (l975) . 
Regarding patterns of resistance, Hall (1975) found no 
strain resistant to any antimicrobial unless resistant to 
penicillin and ampicillin . This was not true in my study . 
Two of the strains I tested were resistant to erythromycin 
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only, and one strain was resistant to neomycin only . Genes 
for resistance to these antibiotics (penicillin, ampicillin, 
erythromycin, and neomycin) may or may not be found on the 
same plasmid (Tompkins and Falkow, 1986) . Therefore, 
resistance of a strain to various antibiotics without 
resistance to penicillin and ampicillin may be explained on 
this basis. Even though resistance to the macrolides 
(er ythromycin, etc.), aminoglycosides (neomycin, tobramycin, 
gentamycin, amikacin, etc.) and penicillins (excluding the 
PRP's) may be carried on the same plasmid, mechanisms of 
resistance to these antimicrobials vary (Tompkins and Falkow, 
1986) . Resistance to the penicillins and cephalosporins is 
due to enzymatic hydrolysis of the B-lactam ring; resistance 
to the aminoglycosides takes place through interference with 
transport of the antibiotic into the cell; and resistance to 
erythromycin ~s due to modification of 23S RNA (Tompkins and 
Falkow, 1986). 
The percentage of strains resistant to penicillin and 
ampicillin only, has increased along with increase in overall 
resistance to antimicrobials. Hall (1975) found 55.1% 
resistance to penicillin and ampicillin only, compared with 
my results of 63.9%. Both studies showed 100% cross-
resistance between these two drugs . It has long been 
recognized (Nahhas, personal communication) that resistance 
to penicillin is always accompanied by resistance to 
ampicillin . 
Multiple resistance occurred in 23.9% of the strains 
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Hall studied compared to 20 . 0% of the strains I studied . 
This does not necessarily mean that multiple resistance in ~ . 
aureus strains has decreased in the Stockton community . 
Streptomycin and/or triple sulfa (SSS) were present in 13 . 7% 
of the multiply-resistant strains identified in Hall's study, 
but were not tested in this study . These drugs are rarely 
used today . Because of toxicity, those sulfonamides which 
are used, are administered topically; the exception being 
short acting sulfonamides in combination with trimethoprim, 
often utilized in urinary tract infections (Norton, 1986) . 
The sulfa drug tested in the present study was trimethoprim 
in combination with sulfamethoxazole (TXS). No resistance was 
found. 
The high incidence of multiple resistance lS 
understandable given the variety of mechanisms involved in 
the transfer of R (resistance) plasmids from one bacterium to 
another. Tompkin and Falkow (1986) believe that transduction 
(transmission by a bacteriophage vector) is probably the most 
common mean of plasmid transmission among staphylococci. 
Transmission of plasmids may also occur through conjugation . 
One strand of DNA from the double-stranded plasmid is 
transferred from the donor to the recipient, followed by 
synthesis of complementary strands of DNA in ' each mating 
partner. Evidence suggests that determinants for methicillin-
resistance as well as resistance to other antimicrobials 
reside in ~. epidermidis strains which are part of the normal 
flora of patients and hospital staff. These determinants 
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provide a reservo1r of resistance genes which can be passed 
to the more virulent ~ . aureus through conjugation (Archer 
(in Neu, 1988)) . R plasmids, according to Tompkin and Falkow 
(1986) , can also be obtained by uptake from the surrounding 
environment, a process known as transformation . 
Genes coding for antimicrobial resistance are not always 
transferred as part of a plasmid . Some plasmodal genes, 
termed transposition elements or transposons, have the 
capability to move from one DNA element of a cell to another 
(from plasmid to plasmid, plasmid to chromosome, or vice 
versa) . 
Only three (2 . 7% total) of the~. aureus isolates 
studied, were methicillin-resistant. One of these strains 
was detected only after the additional 24 hour incubation 
period at 32C. In other words, the standard laboratory 
procedures used for detecting resistance to antimicrobials at 
Dameron Hospital were not sufficient to detect methicillin-
resistance in the case of strain #11126. The new procedures 
recommended for detecting MRSA should be used in order to 
detect all methicillin-resistant strains . 
Two of the three MRSA strains (#'s 10284 and 11126) came 
from patients who were brought to the emergency room of 
Dameron Hospital about three months apart, but from the same 
local convalescent home. The third strain (#11299) came from 
a resident of another convalescent home in Stockton. All 
three isolates were recovered from decubeti (bed sores) which 
had become infected at the convalescent homes . They were not 
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hospital acquired . This is in contrast with national figures 
reported by J.E . McGowen, Jr . (in Neu, 1988) of Gray Memorial 
Hospital, Atlanta, Georgia . He states that of all bacterial 
strains isolated from nosocomial infections ~n 1984, MRSA 
accounted for 11 . 3% of large teaching hospital strains, 6% of 
nonteaching hospital strains, and 4 . 6% of small teaching 
hospital strains . In addition, J . E . McGowen Jr . reports 
increased methicillin-resistance (28 to 43%) among ~- aureus 
strains isolated from blood cultures at Grady Memorial 
Hospital between 1984 and 1986 . 
Trends of increased resistance to methicillin are 
worldwide . Acar reports that 20-25% of ~ - aureus strains 
isolated ~n French hospitals are methicillin-resistant, and 
in Italy methicillin-resistance in ~ - aureus isolates 
increased from 6% in 1981 to 26% in 1986 as reported by 
Schito (in Neu, 1988) . 
All three methicillin (oxacillin)-resistant strains 
isolated in this study were also resistant to penicillin, 
ampicillin, cefazolin, erythromycin, neomycin, and 
tobramycin . The resistance of MRSA to antibiotics ~n 
addition to methicillin has been noted by many (Kayser and 
Santanam, 1975; McNeil and Solomon, 1985; Thornsberry and 
Jorgensen, 1985) Welch and Southern (1984) report that MRSA 
almost always shows resistance to the other semisynthetic 
penicllinase-resistant penicllins as well as penicillin, 
ampicillin, chloramphenicol, erythromycin, and tobramycin . 
Although the MRSA strains I studied did not show resistance 
to chloramphenicol, they were more multiply-resistant than 
any of the methicillin-susceptible isolates . 
There seems to be a direct correlation between the 
increase in methicillin-resistance and resistance to other 
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antimicrobials . Dr . Schito (in Neu, 1988) suggests that the 
significant increase in staphylococcal resistance to 
practically all antimicrobials (excluding tetracycline) is 
related to the increasing proportion of methicillin-resistant 
strains 1n hospitals . Between 1984 and 1986, resistance to 
cefoxitin and tobramycin remained essentially unchanged among 
methicillin-susceptible staphylococci while increasing from 
38-53% for cefoxitin and 43-59% for tobramycin among 
methicillin-resistant strains in Italy . According to R . A. 
Skurray (in Neu, 1988), MRSA resistance determinants for 
antimicrobials including methcillin, erythromycin, 
rifampicin, streptomycin, sulfonamides, tetracycline are 
chromosomally encoded . Skurry (in Neu, 1988) suggests that 
some of these determinants were plasmid encoded in strains 
isolated in Australia prior to 1970, but have subsequently 
become chromosome encoded through transposition and site-
specific-integration. 
Kayser and Muller (1983) describe two major mechanisms 
of staphylococcal resistance to the B-lactam antibiotics 
(penicillin, ampicillin, the cephalosporins, and 
semisynthetic penicillinase-resistant penicillins). These 
include a plasmid-mediated drug inactivation due to the 
production of penicillinase, as described earlier, and a 
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chromosomally-mediated intrinsic resistance. Intrinsically 
resistant strains have an alternative penicillin binding 
protein known as either PBP-2 or PBP-2a which shows lesser 
affinity for B-lactams (Jorgensen and Thornsberry, 1987) . 
Since the altered PBP has a diminished affinity for all B-
lactam antibiotics, strains with this characteristic should 
be reported as resistant to all B-lactams regardless of in 
vitro results (Jorgensen and Thornsberry, 1987) . 
Methicillin-resistance due to hyperproduction of 
penicillinase, has recently been recognized. Overproduction 
of penicillinase causes moderate hydrolysis of the PRP's, 
particularly oxacillin. This mechanism of resistance to the 
PRP's is termed "borderline" or "acquired" resistance and 
appears to occur only in ~. aureus (Jorgensen and 
Thornsberry, 1987). 
Some unusual results for oxacillin and nafcillin by the 
Kirby-Bauer method are shown in Table VI. For both, the 48 
hour results show more resistance than the 24 hour results. 
Strain #'s 9849 and 11915 from Table III, and 9904 and 12175 
from Table V, are examples of this phenomenon. These strains 
were not resistant by the MIC method . In addition, the 24 
hour results for oxacillin and nafcillin indicate a higher 
percentage of resistance than did the results of the MIC 
method. Strain #11382 from Table III and #'s 9475 and 12168 
from Table V exemplify this. As indicated in the "Results" 
section, only the methicillin results by the disc diffusion 
method coincide with the oxacillin results by the Kirby-Bauer 
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method . Reasons for this are unclear. There still seems to 
be a great deal of controversy as to which method of 
susceptibility testing is most reliable . Many scientists are 
investigating this problem (Thornsberry and McDougal, 1983; 
Hansen and Freedy, 1984; Jorgensen et al., 1984 ; Woolfrey et 
al., 1984; Robinson et al., 1986) . Barry and Jones (1987 : 
p . 1897) state, "Definition of an optimal, but yet practical 
method for absolute detect ion of all staphylococcal 
resistance to the penicillinase-resistant penicillins seems 
impossible . " 
Conflicting results between the two methods compared in 
this project, may be due to the fact that zone sizes obtained 
with the Kirby-Bauer method are affected by B-lactamase 
production. According to McDougal and Thornsberry (1984), S . 
aureus strains with the same MIC's, exhibit varying zone 
sizes depending on whether or not B-lactamase is produced . 
Hyperproducers of B-lactamase often exhibit zones of 
inhibition at the breakpoint between susceptible and 
resistant (Campos, 1986), making results difficult to 
avaluate. An additional complication rests in the 
possibility that the salt supplement needed to enhance growth 
of heteroresistant staphylococci, may at the same time 
promote production and release of B-lactamase (McDougal and 
Thornsberry, 1986) . 
Another factor leading to discrepancies between disc 
diffusion and MIC results lS that the disc potency and zone 
interpretations set forth by the National Committee for 
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Clinical Laboratory Standards (NCCLS) do not correlate well 
with the MIC results obtained by recommended procedures for 
susceptibility testing (McDougal and Thornsberry, 1984; 
Coudron et al . , 1986). While the NCCLS has approved using 
the disc potencies and interpretation ranges shown in 
Appendix IV, McDougal and Thornsberry (1984) recommend 10, 4, 
and 4 ~g with resistance at ~11, ~12, and ~12 mm for 
methicillin, oxacillin, and nafcillin, respectively. Use of 
the less potent discs in this study, resulted in smaller zone 
sizes than would have been obtained by following the 
procedures recommended by McDougal and Thornsberry (1984) . 
Results of this study and others indicate that the MIC 
method of susceptibility testing is more reliable than the 
Kirby-Bauer method for detecting true heteroresistance in ~ . 
aureus. Anyone using the Kirby-Bauer method for detecting 
methicillin-resistance should limit the incubation period to 
24 hours. Mulligan et al . (1987) found that 34% of 139 
isolates he tested were resistant at 48 hours with the Kirby-
Bauer method, but had MIC ' s ~1 . 0 ~g/ml . Coudron et al . 
(1986) states that the Kirby-Bauer method for detection of 
MRSA works best if plates are read after 18 hours incubation . 
Currently, investigators are placing emphasis on 
distinguishing between acquired resistance and 
heteroresistance . It is unclear whether acquired resistance 
can cause clinical failure of the PRP's and cephaolosporins . 
Some authors (McDougal and Thornsberry, 1984; Mulligan et 
al., 1987) state that until investigators know for sure, 
serious infections due to MRSA, intrinsic or otherwise, may 
need to be treated with vancomycin (the drug of choice for 
treating heteroresistant or intrinsically resistant 
staphylococci) despite its toxicity and cost . 
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INCUBATION PERIOD 
cv 
24 HOURS 1 
48 HOURS 1 
24 HOURS 
!---· 
48 HOURS 
TABLE I 
Biochemical and Enzymatic Activity of 
S. aureus Isolates at 24 and 48 Hours 
PERCENT POSITIVE 
-
MS NIT NOV PGR IDX VP OPT PHO BE 
-
100 96 1 0 95 95 100 99 0 
-
99 95 1 0 99 96 99 98 0 
PERCENT POSITIVE 
--
URE RAF lAC TRE MNS NaCI SOR MAN DNAse 
67 3 73 99 99 100 1 91 -
88 32 80 98 99 99 1 95 100 
-------
r------
PYR ARG PGT 
-
·- -- ·- · ----
75 91 84 
.. 
78 96 92 
'----- -
- -
... 
·--- -
- - - - -
HEM COAG 
- - - · 
98 95 
- · --
-- - - - -· 
98 95 
N . 
co 
ISOLATE • TE ox 
8804 0.5 0 .25 
8842 0.5 0 .5 
8859 0.5 0 .25 
8947 0 .5 0.25 
8964 0 .5 0 .25 
8986 0 .5 0.25 
8987 0.5 0 .25 
9110 0.5 0.25 
9235 0 .5 0.25 
9252 0 .5 0 .25 
9273 0 .5 0 .5 
9352 0 .5 0.25 
9474 0 .5 0.25 
9600 128 0 .25 
9757 0 .5 0.25 
9826 0 .5 0.25 
9849 0 .5 0 .5 
10168 0 .5 0 .25 
10252 0 .5 0.25 
10295 0 .5 0.25 
10347 0.5 0 .25 
10363 0 .5 0.25 
10399 0 .5 0.25 
10439 0 .5 0.25 
----
-. 
TABLE II 
MIC's (mcg/ml) of 13 Antimicrobials 
(In-Patient Isolates) 
AMP PEN VA Cfz E Cd GM Rif 
-- ----
1 1 2 1 0 .5 0 .25 1 2 
>8 8 2 1 0.5 . 0.25 1 2 
>8 >8 2 1 4 0 .25 1 2 
>8 >8 2 1 0.25 0.25 1 2 
0.12 0 .03 2 1 0 .25 0.25 1 2 
-- - - -
>8 >8 2 1 0 .5 0.25 1 2 
4 8 2 1 0 .5 0.25 1 2 
4 2 2 1 0 .5 0 .25 1 2 
>8 >8 2 1 0 .5 0 .25 1 2 
4 4 2 1 0.25 0 .25 1 2 
>8 >8 2 1 0 .5 0.25 1 2 
-· 
>8 >8 2 1 0 .5 0 .25 1 2 
2 4 2 1 0 .5 0 .25 1 2 
- f------· 
8 1 2 1 0 .5 0 .25 1 2 
0 .25 0 .25 2 1 0.25 0.25 1 2 
0 .12 0.03 2 1 0 .5 0.25 1 2 
>8 >8 2 1 0 .25 0 .25 1 2 
8 >8 2 1 0 .5 0.25 >6 2 
----
4 8 2 1 4 0 .25 1 2 
2 4 2 1 0 .25 0 .25 >6 >4 
1 0 .5 2 1 0 .5 0.25 1 2 
1 0 .5 2 1 0 .5 0.25 1 2 
0.25 0.12 2 1 0 .5 0.25 1 2 
2 1 2 1 >4 0.25 1 2 
·-·-- - -- --------- ----- - - . -
TXS c Crt 
r-· ---
2/38 8 8 
-- -- · -----·-
2/38 8 8 
- -- ·- --
2/38 8 8 
--r--
2/38 8 8 
2/38 8 8 
r--- --- ---·- - ·-- ----
2/38 8 8 
-- ·- ·-
2/38 8 8 
. --
- ----
2/38 8 8 
r----
2/38 8 8 
.... 
2/38 8 8 
-+------
2/38 8 8 
-- - --- -- ---
2/38 8 8 
--·- ---- ---· 
2/38 8 8 
-
2/38 8 8 f----·---, 
2/38 8 8 
-- -- j 
2/38 8 8 
·-- --·-
2/38 8 8 
2/38 8 8 
·- - -- -- ---
2/38 8 8 
--
2/38 8 8 
---- r-----
2/38 8 8 
- -----
2/38 8 8 
·- --
2/38 8 8 
--
2/38 8 --~--
- - - ---- - -
N 
\0 
ISOLATE • TE ox 
10461 0 .5 0 .25 
10545 0 .5 0.25 
-- · 
10748 . 0 .5 0 .25 
r---
10880 0 .5 0.25 
-- · 
10941 0.5 0 .25 
·-
11060 0 .5 0.25 
11130 0.5 0.25 
11142 0 .5 0.25 
11312 0 .5 0.25 
11382 0.5 0 .25 
11383 1 0 .25 
11694 0 .5 0 .25 
11728 0 .5 0.25 
11811 0.5 0 .25 
11878 0 .5 0.25 
11910 0.5 0 .25 
11915 0.5 0 .5 
11964 0.5 0.25 
12148 8 0 .25 
12154 0 .5 0 .25 
12232 0.5 0 .25 
12241 0 .5 0 .25 
63459 0.5 0.25 
-
TABLE II (cont.) 
MIC's (mcg/ml) of 13 Antimicrobials 
(In-Patient Isolates) 
AMP PEN VA Cfz E Cd GM Rif 
1 1 2 1 0.25 0 .25 1 2 
0.12 0.03 2 1 0 .5 0.25 1 2 
1 1 2 1 0.5 0.25 1 2 
- -- -- --· 
1 0.25 2 1 0 .5 0 .25 1 2 
0.12 0 .03 2 1 >4 0 .25 1 2 
--- ·--·-
>8 >8 2 1 0 .5 0 .25 1 2 
2 2 2 1 0.5 1 1 2 
2 1 2 1 >4 0 .25 1 2 
4 >8 2 1 >4 0 .25 1 2 
8 >8 2 1 4 0.25 1 2 
8 >8 2 1 0.5 0.25 1 2 
-
1 1 2 1 0 .25 0 .25 1 2 
2 1 2 1 2 0 .25 1 2 
1 1 2 1 0.25 0.25 1 2 
2 1 2 1 0.25 0 .25 1 2 
.. 
4 2 2 1 >4 0.25 1 2 
4 8 2 1 >4 0.25 1 2 
1 0.5 2 1 0.25 0 .25 1 2 
1 0 .25 2 1 0.25 0 .25 1 2 
8 8 2 1 0.25 0.25 1 2 
2 1 2 1 0.25 0.25 1 2 
--
1 0 .5 2 1 >4 0 .25 1 2 
0.12 0 .03 2 1 0 .5 0 .25 1 2 
-
TXS c Crt 
. -
2/38 8 8 
- - --
2/38 8 8 
--f---·-- ----~ 
2/38 8 8 
·- ----· 
2/38 8 8 
·-
2/38 8 8 
·-· -·--·· 
2/38 8 8 
.. 
2/38 8 8 
·-· - - -
2/38 8 8 
2/38 8 8 
·------
2/38 8 8 
2/38 8 8 
--- --·- ----· 
2/38 8 8 
--
.. 
2/38 8 8 I 
2/38 8 8 
··- f--- -- r----
2/38 8 8 
--
--- · ·--·- ---
2/38 8 8 
-- · 
2/38 8 8 f----· 
2/38 8 8 
-- - - ·- · 
2/38 8 8 
2/38 8 8 
--- ---- -
2/38 8 8 
r·--- ----- ·--- ·---
2/38 8 8 
--
2/38 8 8 
-- r-·--- - VJ 0 
ISOLATE • OX-24 
8804 14 
8842 12 
8859 16 
8947 14 
8964 23 
8986 11 
8987 19 
9110 17 
9235 18 
9252 20 
9273 0 
9352 16 
9474 19 
9600 19 
9757 23 
9826 23 ' 
9849 14 
10168 23 
10252 22 
- -
10295 21 
TABLE III 
Zones of Inhibition (mm)* to Six Antimicrobials 
(In-Patient Isolates) 
OX-48 ME-24 ME-48 NA-24 NA-48 NEO 
- - ---
14 19 19 19 19 23 
12 15 15 16 16 24 
16 20 20 17 17 12 
13 16 15 18 14 24 
23 23 23 22 22 22 
-
10 16 14 17 13 22 
- -
c--- . 
15 19 15 19 15 21 
17 19 19 19 19 20 
18 19 19 18 18 22 
20 19 19 19 19 21 
0 14 14 13 13 21 
16 18 18 17 17 21 
r---- - -
17 17 17 18 17 21 
- -
15 17 16 18 16 19 
23 20 20 20 20 20 
20 20 18 20 20 20 
·-
0 14 13 14 10 22 
--
23 23 23 23 23 15 
17 20 18 20 17 21 
21 22 22 21 21 14 
TOB AMIIC 
-- ·- ---- --
25 23 
- - - - -
26 23 
·1-- - ·- ----·-
24 21 
--- -1-- -- - - · 
27 26 1-------
26 25 
-- ·- ··- ·- --
25 23 
~·------- - •. 
25 22 
· ·-- ---
24 23 
·r--- --- ·- --·- ·-
24 22 
--------
25 23 
-- r---- - ---
24 23 
--- - --
24 23 
-- f---- - - · 
24 23 
22 20 
:---- ·---- -
23 20 
- ---- - -
23 22 
----- ---~~ ~- - ;>-
- ---- --
26 24 
11 19 
---- - ---- -- - ---
10347 21 15 21 15 21 15 20 24 23 
··- - - -----· 
10363 20 15 21 17 20 16 21 24 24 
-- -
10399 24 24 23 23 23 23 20 22 22 
- ---- - -
10439 21 19 20 20 20 19 20 23 21 
- · -- · - ·-
"Zone Sizes Measured after 24 and 48 Hours Incubation for Methicillin, Oxacillin, and Nafcill in 
w 
...... 
ISOLATE # OX-24 
r---· 
10461 20 
10545 25 
10748 19 
10880 20 
10941 24 
1l060 15 
11130 16 
11142 17 
11312 17 
11382 0 
11383 17 
11694 17 
11728 15 
11811 23 
11878 16 
11910 20 
11915 14 
11964 18 
12148 19 
12154 12 
12232 21 
12241 20 
63459 25 
TABLE III (cont.) 
Zones of Inhibition (mm)* to Six Antimicrobials 
(In-Patient Isolates) 
OX-48 ME-24 ME-48 NA-24 NA-48 NEO TOB AMIK 
'---- - ·- ·--
18 20 16 20 14 19 22 20 
-- ---- -· 
25 22 22 22 22 20 22 20 r------- -- - ----- - - ------
19 20 20 16 16 21 23 21 
-----
20 20 20 20 20 20 23 21 
-- - - - - -·---··· 
24 21 21 23 23 21 24 23 
-- ------ -- --- ·--··--
12 14 14 15 14 20 23 22 
---·----
14 17 16 18 16 21 24 23 
16 20 17 17 16 20 23 22 
·- ·- ·--
17 19 19 18 18 20 23 21 
·-- - - ----
0 15 15 14 14 20 24 22 
-- ------· 
12 17 14 16 16 21 24 22 
-- r-- ---- - --·--
15 19 16 19 16 22 26 15 
r----------- · 
13 17 16 18 15 20 23 22 
23 21 21 23 23 23 26 ·----·-, 25 ' r------~ 
16 18 16 18 16 23 25 24 
------------ -
16 20 16 20 16 23 25 25 
0 16 0 13 0 21 24 22 
----- >----------
15 19 16 18 15 22 25 23 r--·---- - --- .. ·--
14 18 15 18 13 23 25 24 
- --- --·--·--11 14 13 14 9 25 28 26 
-- -· 16 19 16 19 15 22 25 24 
- --r-------- · - - - ···- ------15 17 16 17 16 23 25 24 
-· - - ---
25 23 23 21 21 20 23 23 
- .. - - -
-· 
*Zone Sizes Measured after 24 and 48 Hour s Incubation for f'1ethicillin. Oxacillin. and Nafcillin 
w 
N 
ISOLATE • TE ox 
8782 0 .5 0 .25 
8799 0 .5 0 .25 
8898 0.5 0.25 
8899 0.5 0 .25 
8920 0 .5 0.25 
9033 0 .5 0 .25 
9100 0 .5 0.25 
9114 0 .5 0 .25 
9116 0.5 0 .25 
9475 0 .5 0 .25 
9487 128 0 .25 
9506 0 .5 0.25 
9519 0.5 0.25 
9538 0 .5 0 .25 
9641 0 .5 0 .25 
9798 0 .5 0 .25 
9854 0 .5 0 .5 
9904 0 .5 0.25 
9914 0 .5 0.25 
9925 0 .5 0.25 
9987 0 .5 0 .25 
10025 0 .5 0 .25 
10097 0 .5 0 .25 
10107 0 .5 0 .25 
TABLE IV 
MIC's (mcg/ml) of 13 Antimicrobials 
(Out-Patient Isolates) 
AMP PEN VA Cfz E Cd GM Rif 
1 0 .5 2 1 0.5 0 .5 1 2 
·-
4 8 2 1 0.5 0 .25 1 2 
8 >8 2 1 0 .5 0 .25 1 2 
-- --- --
2 1 2 1 0.5 0 .25 1 2 
--
2 4 2 1 0 .5 0.25 1 2 
-
2 1 2 1 0 .5 0 .25 1 2 
- ·-
1 0 .5 2 1 0 .5 0 .25 1 2 
8 8 2 1 0 .5 0.25 1 2 
2 1 2 1 0 .5 0 .25 1 2 
>8 >8 2 1 0 .5 0.25 1 2 
2 4 2 1 0 .5 0 .25 1 2 
1 0 .5 2 1 0 .5 0 .25 1 2 
-t------ · 
8 4 2 1 0.5 0.25 1 2 
TXS c crt 
-·--r----·-
2/38 8 8 
-- · ---
2/38 8 8 
-- ---
r----
2/38 8 8 
- -- -· 
2/38 8 8 .. __ 
2/38 8 8 
--- --·-- -----
2/38 8 8 
- --- ---
_____ .. ____  
2/38 8 8 
-- --- ·---· ---
2/38 8 8 
--r----- - - - -
2/38 8 8 
-- -- - ·- ---
2/38 8 8 
2/38 8 8 
-- - ·- - ·-
2/38 8 8 
- - ----· - - -
2/38 8 8 
-
__ .. .. ___  
·- -- ... 
0 .12 0.03 2 1 >4 0 .25 1 2 2/38 8 8 
--- ·- - - -···· - --··- -
2 2 2 1 0.25 0 .25 1 2 2/38 8 8 
... 
·- --- ------ - -- --- ·-· 
2 4 2 1 0.25 0 .25 1 2 2/38 8 8 
.. _ 
- ·- ·----- --·1 
2 2 2 1 0 .5 0 .25 1 2 2/38 8 8 
---
8 >8 2 1 0 .5 0 .25 1 2 2/38 8 8 
- - -
1 0.25 2 1 0.5 0 .25 1 2 2/38 8 8 
-- - - --- - - -- -
2 1 2 1 0 .5 0 .25 1 2 2/38 8 8 
- --
1 1 2 1 >4 >4 1 2 2/38 8 8 
- - - -- -·---
0.12 0 .03 2 1 0 .5 0 .25 1 2 2/38 8 8 
-
0 .1 2 0.03 2 1 0.5 0 .25 1 2 2/38 8 8 
-·--·-· 
0.5 0.25 2 1 0.25 0 .25 1 2 2/38 8 8 
----------------- --- · - -
w 
w 
ISOLATE • TE ox 
1----
10112 0 .5 0.25 
10119 0 .5 0 .25 
10131 0 .5 0 .25 
10199 0 .5 0 .25 
10205 0 .5 0 .25 
10207 0 .5 0.25 
10284 0 .5 >8 
10420 0 .5 0 .25 
--
10455 0 .5 0 .25 
10477 0.5 0 .25 
10494 0 .5 0 .25 
10542 0 .5 0 .25 
10620 0.5 0.25 
-
10638 0.5 0.25 
-· 
10642 0.5 0.25 
10757 0.5 0.25 
- --· 
10784 0.5 0 .25 
10820 128 0.25 
10896 0.5 0.25 
10940 0 .5 0 .25 
11073 0 .5 0 .25 
-
11122 0 .5 0 .25 
11126 4 0 .25. 8 
__ 1_1_~:t~ 0.5 0.25 
TABLE IV (cont.) 
MIC's (mcg/ml) of 13 Antimicrobials 
(Out-Patient Isolates) 
AMP PEN VA Cfz E Cd 6M Rif 
1 0 .5 2 1 0.25 0.25 1 2 
--r-- -
1 2 2 1 0.5 0 .25 >6 2 
-- --
1 0 .5 2 1 >4 0 .5 1 2 
0.5 0 .25 2 1 0 .25 0.25 1 2 
- ----
0.12 0.03 2 1 2 0 .25 1 2 
-- - --r----- --·--
1 0 .5 2 1 0 .5 0 .25 >6 2 
- -- · --
1 1 2 8 >4 0 .5 1 2 
---
1 1 2 1 0.5 0.25 1 2 
-
1 1 2 1 0 .25 0 .25 1 2 
--
0.12 0 .03 2 1 0 .5 0 .25 1 2 
-- · 
1 0.25 2 1 0 .25 1 1 2 
0.5 0.25 2 1 0 .5 0 .25 1 2 
-- - - -· 
0.5 0.25 2 1 0.5 0 .25 1 2 
r-· ---
1 0.5 2 1 0 .5 0 .25 1 2 
·----- ---- --- -- - - --- - --
1 0.5 2 1 0.5 0 .25 1 2 
--
1 0 .5 2 1 0 .5 0 .25 1 2 
1 0 .5 2 1 0 .5 0 .25 1 2 
4 4 2 1 0 .5 0.25 1 2 
---
- · 
1 0.5 2 1 0 .5 0 .25 1 2 
0.25 0.12 2 1 0.25 0.25 1 2 
·--
0.5 0.5 2 1 0.5 0 .25 1 2 
TXS 
2i38 
2/38 
r----
2/38 
·---
2i38 
----
2/38 
r----
2/38 
--·-
2i38 
!---- --
2/38 
-- ----
2/38 
---
2/38 
2/38 
2/38 
----
2/38 
---·-
2i38 
-----
2/38 
-----·-
2/3_iL 
2/38 
2/38 
- --
2/38 
2/38 
2/38 
-- ---f------
0.5 0 .25 2 1 0.5 0 .25 1 2 2/38 
- ·---r----
4 4 2 1 >4 0 .25 1 2 2/38 
2 2 2 1 0 .5 0 .25 1 2 2/38 
c crt 
-
8 8 
. ------
8 8 
8 8 
-
8 8 
r---- - ·-·---· 
8 8 
·- ---- - -------... 
8 8 
- - ---- - --··-
8 8 
------
8 8 
- ---- --- --· 
8 8 
---- - --
8 8 
··--- - ----
8 8 
- --- -------
8 8 
----·--· ··----· 
8 8 
r-- --- -----
8 8 
------ ·- --·-- ---·-·· 
8 8 
.. ------ - -- -
8 8 
8 8 
- --- -----·-
8 8 
-- -- ----
____ , 
8 8 : 
·- I 
8 8 
-- -
8 8 
---- ------
8 8 
·- - - - ------- ··-·-
8 8 
- ------- -- --····- · 
8 8 
w 
.::----
ISOLATE • TE ox 
11299 8 >8 
--
11317 0.5 0.25 
11373 128 0 .25 
11513 0 .5 0 .25 
11520 0.5 0 .25 
11527 0 .5 0 .25 
11603 0 .5 0 .25 
-
11655 0 .5 0 .25 
11696 0 .5 0 .25 
11760 0.5 0.25 
11835 0.5 0.25 
11998 8 0 .25 
12168 0 .5 0.5 
12175 0.5 0.25 
12199 0 .5 0 .25 
12229 0 .5 0.25 
B3350 0 .5 0 .25 
TABLE IV (cont.) 
Mrc·s (mcg/ml) of 13 Antimicrobials 
(Out-Patient Isolates) 
AMP PEN VA Cfz E Cd 6M 
-
4 4 2 1 >4 0 .25 1 
1 1 2 1 0.25 0.25 1 
1 0.5 2 1 0 .5 0 .25 1 
--
0 .12 0.03 2 1 0 .25 0 .25 1 
0.5 0.25 2 1 0 .25 0.25 1 
' 0 .12 0 .03 2 1 0 .25 0.25 1 
2 4 2 1 0.25 0.25 1 
1 0 .5 2 1 0.25 0.25 1 
1 2 2 1 0 .25 0.25 1 
0.12 0 .03 2 1 0 .25 0 .25 1 
2 ,.., 2 1 0 .25 0 .25 1 L.. 
0.12 0.03 2 1 0.25 0.25 1 
-· 
>8 8 2 1 0 .25 0 .25 1 
4 2 2 1 0.25 0.25 1 
0 .12 0 .03 2 1 0 .25 0 .25 1 
0.12 0.03 2 1 0 .25 0.25 1 
0.12 0.03 2 1 0 .5 0 .25 1 
Rif 
--
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
TXS -c-- en 
- -- -·- - -
2/38 8 8 
-·- ----
2/38 8 8 
-- - - -
2/38 8 8 
2/38 8 8 
2/38 8 8 
--·---
2/38 8 8 
-- ·- -' 
2/38 8 8 
. ----
.. _____ 
2/38 8 8 
2/38 8 8 I 
--·-' 
2/38 8 8 
- ··----- ·-
2/38 8 8 
- ---
2/38 8 8 
r-·-·--
2/38 8 8 
2/38 8 8 
·- -- --
2/38 8 8 
-- ·--··-- - - -
2/38 8 8 
-- ·-- ·- --
2/38 8 8 
·---·----
-- ---
-- r-- ·- -
-1----- -- -
-- - ·- ·· 
- ------
w 
Vl 
ISOLATE • 
8782 
8799 
8898 
1----
8899 
8920 
9033 
9100 
9114 
r---
91 16 
9475 
9487 
9506 
- -9519 
9538 
9641 
9798 
9854 
9904 
9914 
9925 
9987 
10025 
10097 
10107 
OX-24 
20 
17 
17 
18 
19 
; 
22 
22 
19 
TABLE V 
Zones of Inhibition (mm)* to Six Antimicrobials 
(Out-Patient Isolates) 
OX-48 ME-24 ME-48 NA-24 NA-48 NEO TOB 
--- -
20 20 20 21 21 22 24 
r---- - ---
17 17 17 17 17 25 26 
17 20 20 20 20 22 26 
-··- --· 
18 20 20 21 21 22 27 
-
19 20 20 20 20 23 25 
--------- ---- --
22 22 22 22 22 22 25 
-------
22 20 20 22 22 20 25 
- --
16 21 21 19 19 20 25 
AMIK 
------ ---
23 
- - ------·-
23 
- --- --· 
24 
r-----·· ----
24 
-----
24 
- - - ··- -·--·-· 
24 
r-------
23 
-- ·- ·- --·-
23 
-- - - --
·- -
14 12 18 17 17 13 20 23 22 +---------
10 0 17 14 15 10 20 23 20 
-- -- ---- ----- - --
20 17 19 19 19 19 20 22 21 
- - -- ----
23 20 20 20 21 21 21 23 21 
-- ·- ·· r-- --- -
19 14 19 15 18 14 20 22 20 
- -----·· ·-··--· 
15 12 22 22 23 23 20 22 22 
-- --- - -- -- - --- ---------1---- -- - - ---
18 14 19 19 19 19 20 23 21 
---- - ~-- -----
22 22 22 22 22 22 19 23 21 
-- -- --- ---
14 0 19 19 17 15 21 24 23 
-- - -----
12 0 15 13 13 0 18 20 20 
-- ---- - --
20 17 20 17 20 17 19 23 20 
-- - - - - - -
24 19 21 19 23 18 24 28 26 r--- --------- ----
19 14 20 14 20 15 21 23 23 
- ··- ·--- ----·----- - -
30 30 27 27 27 27 23 26 25 
---- -
23 23 22 22 21 21 20 23 22 
-- - ---
31 31 31 31 30 30 25 28 27 
*Zone Sizes Measured after 24 and 48 Hours Incubation for Methicillin, Oxacillin, and Nafcillin 
\,....) 
0'> 
ISOLATE • OX-24 
10112 21 
10119 21 
10131 17 
10199 22 
10205 26 
10207 20 
10284 0 
10420 19 
10455 19 
10477 25 
10494 21 
10542 21 
--
10620 20 
10638 19 
- ---
10642 23 
10757 21 
------
10784 20 
10820 20 
10896 22 
10940 23 
11073 15 
11122 21 
11126 0 
11242 20 
TABLE V (cont.) 
Zones of Inhibition (mm)* to Six Antimicrobials 
(Out-Patient Isolates) 
OX-48 ME-24 ME-48 NA-24 NA-48 NEO TOB AMI I( 
-- f-· -- - - ------- - -- ---- -
19 20 17 20 17 21 25 23 
- ---------
19 20 20 20 20 15 13 20 
---- - - --
- - --- - ----
15 20 17 18 16 19 22 20 
----- -- - - - -- -----~- - ·- -- -----
22 19 19 20 20 20 23 21 
---- ---- -- --- ··· ------- - -·- ·-
26 25 25 24 24 14 25 23 
- ----- -
f---- - - - ----- '--------- ------- ·- --- - ---·· - - --- - ····-- --- ·-· 
17 21 19 22 17 14 11 19 
- ---- - --
f-------
0 0 0 0 0 14 12 21 
-- - - --- - --- - ---- -- - ----~-- ----
16 19 17 19 16 19 23 20 
- ----- ---- - - -
17 19 19 19 17 18 22 22 
-
f----- - ---
25 24 24 23 23 19 22 21 
-- - ----------- f-- - --- f--- - -- -- -- - -
21 19 19 20 20 18 22 21 
- --- --- - ----- - ---· - ------ -
21 21 21 21 21 23 25 23 
--- - -- --- ------- - -- -- - ---- -- ---
20 19 19 21 21 19 20 22 
-- -- - -· -· ---- -
14 21 21 21 21 20 24 23 
-- -- - - - -- - - - -- ·- - ---- -- - --- -- -- ----· 
23 22 22 21 21 20 22 21 
- - - - - -- - ------ ---- --
21 20 20 21 21 20 23 22 
-- - ------ - ----- --- ---- -- -- ------ - --------- - -·- ··- ---- ·-· 
20 21 21 
- - 20 20 19 23 21 I _ __ _ , 
20 20 20 20 20 20 23 22 
-- -- ~------ ---------
22 20 20 21 21 21 24 23 
------
23 21 21 22 22 20 24 23 
-- -· - -- --- --
14 18 17 16 16 21 25 24 
- - -- - - - - - - --
21 21 21 21 21 21 25 24 
--- - - -- -
0 0 0 0 0 14 12 20 
-- -- -- ------ - -- - --
20 20 20 20 20 21 24 23 
*Zone Sizes Measured after 24 and 48 Hours lncubalion for Methicillin, Oxacillin, and Nafcillin 
w 
....... 
ISOLATE • OX-24 
-- ---
11299 0 
11317 20 
11373 23 
--
11513 28 
11520 24 
11527 25 
11603 21 
11655 21 
11696 23 
-
11760 21 
11835 20 
11998 25 
r-· 
12168 0 
12175 17 
12199 24 
12229 23 
--
B3350 24 
TABLE V (cont.) 
Zones of Inhibition (mm)* to Six Antimicrobials 
(Out-Patient Isolates) 
OX-48 ME-24 ME-48 NA-24 NA-48 NEO TOO AMIIC 
--c------ -- - ·--- - ----- --·-
0 0 0 0 0 14 12 21 
- ~----- - --- -
20 2_.!__ 21 21 21 20 23 22 
--- - ----·-
23 22 22 24 24 23 26 24 
·- ·--·-·-··-~-
28 26 26 27 27 20 24 23 
----- ---·---r-·-- -· -----·- -·----
24 23 23 24 . 24 22 25 23 
- --- - --- -- --- -----
25 23 23 23 23 20 24 21 
-- - -
21 20 20 20 20 22 24 23 
· ··- ·- ----- - --···--- ---
21 20 20 20 20 20 24 22 
-- - - --- ---- - -
23 23 23 23 23 22 25 23 f---------
-·- ··--·-·- --
17 21 15 19 18 19 23 20 
- ·---!------------ ------
16 17 16 19 16 21 25 23 
r-·------
25 23 23 23 23 22 24 24 
--- f--- ·- ----
0 11 11 0 0 24 28 26 
- - - - ---·-· ·--··-- -- - -- --
14 16 14 17 14 22 19 23 
- ---- --
24 23 23 22 22 25 27 25 
-- - ------- ·---~ 
23 21 21 22 22 24 25 24 
-
·f---- - - - - - ····-- - - - - - ·- -----·1 
24 21 21 21 21 19 22 20 ! f--- -- -j 
I 
·---- 1---------· 
-- --
-- ·- --
. --- - ·--·----
·- ------
*Zone Sizes Measured after 24 and 48 Hours Incubation for Methicillin, Oxacillin, and Nafcillin 
(;...) 
(X) 
TABLE VI 
Resistance of S. aureus to 18 Antimicrobials 
--------
ISOLATE PERCENT RESISTANCE 
. 1------ ·- - - -
CLASSIFICA TIOI TE ox AMP PEN VA Cfz E Cd GM Rif TXS c Crt 
·----r-· . - ----
- -----r---- -- --·-- - - ·--·· 
-
---- ·· r-·-- ··- -- ·- ·- ·-· 
In Patient (n 47) 2.1 0.0 89.4 89 .4 0.0 0 .0 21.3 0.0 4.3 2.1 0 .0 0 .0 0.0 
- ·- ---·- - - --- ··-----
-----· ---- ·- -- --
Out Patient (n=65) 4.6 4 .6 81.5 81 .5 0.0 4 .6 9.2 1.5 3 .1 0 .0 0 .0 0.0 o·.o 
-·- - ----
-- ---
Total (n=112) 3 .6 2.7 84.8 84.8 0.0 2 .7 14.3 0 .9 3.6 0 .9 0.0 0 .0 0 .0 
-- -- '--· ·- ·--- · r------.. 
-· ··- - ·-- - --- ·--- - --
-- · ---·- ----
-
.. 
-------· - ···---r------1 
. 
-- ·--- ·- ·-
.. 
-- · 
-- ·- --·---- ··· ---·-- -
ISOLATE PERCENT RESISTANCE 
·----- -- -- --- ··· ·- ---
CLASSIFICATION OX-24 OX-48 ME-24 ME-48 NA-24 NA-48 NEO TOO AMIK 
- -- ·--· --- -
'----- --· 
.. _ 
--
. . 
-- ---
- ------ . 
In Patient (n=47) 4.3 10 .6 0 .0 0 .0 0 .0 6 .4 4 .3 4.3 2.1 
---- ·- ---- ----
Out Patient (n=65) 6 .2 10 .8 4 .6 4 .6 6 .2 9.2 7.7 7 .7 0 .0 
·-·-- -----
--~---- ----
Total (n= 112) 5.4 10 .7 2 .7 2.7 3 .6 8 .0 6 .3 6 .3 0 .9 
- - - ---- ---- ---- --- ---
~ Resistance to Oxacillin, Methicillin, and Nafcillin Shown at 24 and 48 Hours 
VJ 
\0 
Table VII 
Antimicrobial Resistance Patterns 
Among In-Patient and Out-Patient Isolates 
(Staphylococcus aureus) 
40 
X Susceptible or Resistant to Various Antimicrobial Groups 
Total (n=112) IP (n=47) OP (n=65) 
RESIST ANT TO: 
None of the Tested Antibiotics 13.4 8.5 15.4 
Single Antibiotic Only: 
E Only 1.8 2.1 1.7 
NEO Only 0.9 i 0.0 1.7 
I 
PEN &. AMP Only 63 .9 61.7 66.0 
I 
PEN. AMP. &. Others: 
PEN, AMP, TE 3.6 2.1 4.6 
PEN, AMP, E 7.4 17.0 1.5 
; 
PEN. AMP, E, Cd 0.9 0.0 1.7 
PEN, AMP, E. NEO 0.9 2.1 0.0 
PEN, AMP, AMIK 0.9 2.1 0.0 
PEN, AMP, GM, TOB 1.8 2.1 1.7 
PEN, AMP.GM,NEO, TOB 0.9 0.0 1.7 
PEN, AMP, GM, NEO, TOB, Rif 0.9 2.1 0.0 
PEN, AMP, OX, ME, NA, CEF, E. I 2.7 0.0 4.7 
NEO,TOB 
IP = In Patient, OP = Out Patient 
Changes in Antimicrobial Resistance 
of S . aureus Strains from Dameron Hospital 
between 1973-74 and 1987 
41 
ANTIMICROBIALS PERCENT RESISTANCE CHANGE IN I TWO-TAILED 
1973-74 (a) 1975 (b) !RESISTANCE PROBABILITY (c) 
PEN 79 84.8 + 5.8 
AMP ! 79 84.8 + 5.8 
E 3.5 14.3 + 9 .0 
NEO 0 6 .3 + 6.3 ' 
GM oj 3 .6 + 3.6 
ME, OX , NAF. CEF 0 2.7 + 2 .7 I 
Cd 01 0 .9 + 0.9j I 
c 01 0 0 
Va 0 0 0 
TE I 15 3 .6! I - 11 .4/ I 
a . Data from Hall (1975) 
b . Data from present study 
c . Probabilities were obtained with the Chi-square 2x2 
contingency table method . 
< 0.3 
< 0 .3 
< 0 .01 
< 0.02 
< 0.10 
< 0.20 
< 0.95 
-
-
< 0 .01 
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APPENDIX I : PRINCIPLES OF BIOCHEMICAL AND ENZYMATIC 
REACTIONS (GRAM POSITIVE COMBO) 
Crystal Violet (CV) 
46 
Growth in the presence of low concentrations of 
crystal violet is used to distinguish streptococci 
(positive) from from staphylococci (mostly negative) . 
Micrococcus Screen (MS) 
Growth in the presence of 0.5 mcg/ml of bacitracin lS 
used to distinguish staphylococci (positive) from 
Micrococci (negative). 
Nitrate (NIT) 
Reduction of nitrate to nitrite is detected by form-
ation of a red color within seconds following addition 
of one drop of 0.8% sulfonic acid and one drop of 0.5% 
N,N- dimethyl alpha-naphthylamine . Streptococci are 
nitrate-negative and most staphylococci are nitrate-
positive . 
Novobiocin (NOV) 
Resistance to low concentrations (5 meg) of 
novobiocin (evidenced by growth) is characteristic of 
Staphylococcus saprophyticus, ~ . xylosus, ~ . cohni, 
and~ . sciuri . Other staphylococci are susceptible to 
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novobiocin . 
PNP-B-D-Glucuronide (PGR) 
The ability of an organism to produce a specific 
glycosidase enzyme is detected by the splitting of a 
beta-napthylamide-carbohydrate complex releasing p-
nitrophenol. A positive test is indicated by a yellow 
color in the well . 
Indoxyl Phosphatase (IDX) 
Hydrolysis of indoxyl phosphate by the enzyme 
indoxyl phosphatase results in an insoluble blue 
compound. Most coagulase and DNase-positive staphylo-
cocci are lOX-positive, although the reaction may take 
more than 18-20 hours to develop . 
Vogues-Proskauer (VP) 
Actylmethylcarbinol, produced from glucose, reacts 
with 5% alpha-naphthol in an alkaline environment to 
form a red complex. One drop of 40% KOH is added to 
the well to alkalinize the contents, followed by one 
drop of 0 . 5% alph-naphthol . A positive reaction 
appears in 2-15 minutes . 
Optochin (OPT) 
Susceptibility to optochin is a characteristic of 
Streptococcus pneumoniae . Ot her streptococci and 
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staphylococci are not inhibited by optochin . This test 
is not essential for the identification of ~ aureus 
or other staphylococci but is required for computer 
identification in generating a biotype number (This 
process is explained in the next section . ) . A 
positive reaction is indicated by growth . 
Phosphatase (PHO) 
Alkaline phosphatase splits p-nitrophenyl phosphate 
into inorganic phosphate and p-nitrophenol . A positive 
test is indicated by a yellow color . 
Bile Esculin (BE) 
Organisms capable of growing ~n 40% bile and 
hydrolyzing esculin are detected by the production of 
a black precipitate resulting from the reaction of the 
hydrolytic product esculetin with ferric citrate . 
Group D streptococci, some viridans streptococci, and 
some Staphylocci are BE-positive. 
Pyrroldonyl-Beta-naphthylamide (PYR) 
Organisms which produce pyrrolidonase split L-
pyrrolidonyl-b-naphthylamide into L-pyrrolidonyl and b 
naphthylamide . After the addition of one drop of 
peptidase reagent, a red color develops within two 
minutes from the combination of b-naphthylamide with 
peptidase . 
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Arginine (ARG) 
Dehydrolization of arginine results in alkalinization 
of the medium . A positive test is indicated by a 
yellow to red color change of the phenol red 
indicator . 
PNP-Beta-D-Galactopyranoside 
The splitting of a b-napthylamide-carbohydrate com-
plex denotes the ability of the organism to produce a 
specific glycosidase enzyme . This is indicated by the 
formation of p-nitro-phenol which is a yellow color. 
Urea (URE) 
The enzyme urease splits urea forming ammonia and 
carbon dioxide . The resulting increase in pH is 
detected by the phenol red indicator changing from 
yellow to red . 
Carbohydrate Fermentation 
Nine sugars and sugar alcohols including raffinose 
(RAF), lactose (LAC), trehalose (TRE), mannose (MNS), 
sorbitol (SOR), arabinose (ARA), ribose (RBS), inulin 
(INU), and mannitol (MAN) are used in fermentation 
studies . The fermentation of a specific carbohydrate 
results in acid formation . The consequent drop in pH 
is detected by the phenol red indicator turninq 
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yellow . 
6.5% NaCl (NACL) 
Tolerance to 6 . 5% sodium chloride is demonstrated by 
growth . Salt tolerance is a characteristic of all 
staphylococci and the enterococcus group of 
streptococci . 
Bacitracin (BAC) 
Susceptibility to low concentrations (0 . 2mcg?) of 
bacitracin is indicated by a lack of growth and is 
characteristic of Streptococcus pyogenes . This test 
is not essential for identification of staphylococci 
but is required for computer identification in 
generating a biotype . 
Pyruvate (PRV) 
Utilization of pyruvate results in acid formation. 
The resultant drop in pH is detected by the phenol red 
indicator turning yellow. 
Beta-Lactamase (BL) 
Following incubation of the trays for 18-20 hours, a 
drop of 400,000 units of a penicillin G suspension 1s 
added to the BL well and trays reincubated for 30 
minutes. A drop of iodine is then added. The 
disappearance of the blue-black color within 10 
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seconds indicates B-lactamase production and therefore 
a positive reaction . The principle of the test is 
based on the splitting of the B-lactam ring forming 
binding sites which are more competitive for iodine 
than starch molecules are. If B-lactamase is present, 
the iodine binds with the B-lactam ring to form a 
colorless reaction. If B-lactamase is not present, 
the iodine will combine with the starch molecules and 
form a blue-black color. 
52 
APPENDIX II : GENERATION OF A BIOTYPE NUMBER 
A SlX digit biotype number is derived from the results 
obtained for each strain. The 18 biochemical tests are 
divided into six groups of three . Negative reactions receive 
a value of zero. Positive results are given a value of one , 
two, or four depending on their vertical location within each 
group . A value of four is assigned to those tests in the top 
horizontal row (CV, NOV, VP, BE, PGT , and LAC) while tests ln 
the middle row receive a value of two (MS, PGR, OPT, PYR, 
URE, and TRE) and results in the bottom row, a value of one 
(NIT, IDX, PHO, ARG, RAF, and MNS) . The six digit 
biotype number is obtained by adding the values for the 
positive tests ln each vertical group . Biotype numbers are 
automatically generated by the computer as an isolate is 
identified to species . 
APPE:NDIX III 
l~IC Interpretive Chart for 13 Antimicrobials 
in Several Dilutions* 
MICROGRAMS I MILLILITER 
r-- -- -· -- -- ·-------·-
Dilutions Sensitive Intermediate Resistant Ant~microbial or Chemotherapeutic Agent 
- - +--------- - --- ----- --·- · 
Te tracycl ine (TE ) 0.5- 8, 128 s.0.5 - 4 8 128- > 128 
r------ ----- - - -- - - - -- ·---- -- - -
Oxacillin (OX) 0 .25-8 s.0 .25- 2 - 4 - >8 
-- -- ---- ·- - ····- - --·--·-- ·---·. -- -·---· 
Ampicillin (AMP) 0.12-8 ~ 0 .03- 0 .12 - 0 .25- >8 
-- - - --- ---- -
Penicillin (PEN) 0 .03-8 ~0 .03- 0 .12 - 0 .25- >8 
- · - --- ·- -------·- · 
Vancomycin (VA) 2- 16 ~2- 4 8- 16 > 16 
- - ----- ·- - r--- - ----- ·- · 
Cephazolin (Cfz) 1- 16 ~ 1 -8 16 > 16 
--- --- ---- - - ·- - - - --- ·- ---·- ··-····--
Erythromycin (E) 0.25-4 s.0 .25- 0 .5 1-4 >4 
_ , 
----- ------ -----·-- --
Clindamycin (Cd) 0 .25-4 <0.25- 0 .5 1 - 4 >4 
--· -- . r--------- - ·- --·-----
Gentamycin (GM) 1 - 4, 6 ~ 1 -4 6 >6 
- -··· --·- - - - ·--- ·-
Rifampin (Rif) 2. 4 ~2 4 >4 
- · -- - - ----- ---· ·-- - ·----- -------- · 
Trimethoprim-sulfamethoxazole (TXS) 8/152. 2/38 Q / 38 8/152 >8/ 152 
- ----- ·- -·- -- · 
Chloramphenicol (C) 8, 16 ~8 16 f--·-
-
Cefotaxime (Cft) 8, 32 s.8 32 
----- - -- - - -
~Dilutions represented by a range are actually a series of twofold 
dilutions. Reproduced from Microscan Gram Positive Combo 
Interpretive Chart, Baxter Scientific Products, Sacramento, 
California . 
> 16 
·---- 1 
>32 ' i 
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APPENDIX IV 
Zone Size Interpretive Chart for 
Six Antimicrobials, Kirby-Bauer Method* 
Antimicrobial or Chemotherapeutic Agent Disc Potency (meg) Zone of Inhibition in Hi11imeters 
·----·--- - -·-- ·--,---- --------····· 
Sensitive Intermediate Resistant 
- -
_ _______ , -- ··· 
Methicillin (ME) 5 214 10-13 ~9 
-- - - --- - - - ··-·· ··-- --~ -·-·---- . 
Oxacillin (OX) 1 213 11-12 ~ 10 
--- ·- - · ---- ·- - -- ----·-- -· 
Nafcillin (NA) 1 ~ 13 11-12 ~ 10 
- - - -- ------- -----··-·- ·---·----- · 
Neomycin (NEO) 30 ~ 17 13-16 ~ 12 
-- ··- - - - ····--··- ---·---
Tobramycin (TOB) 10 ~ 15 13-14 ~ 12 
·-- -·---- - -------·-- ------
Amikacin (AMIK) 30 217 15-16 ~ 14 
------- ---- - ------ - - ---------
*Reproduced from Bacto-Susceptibility Discs, Difco Laboratories, 
Detroit, Michigan . 
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